Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Collplant Holdings ( (CLGN) ) has issued an announcement.
On October 20, 2025, CollPlant Biotechnologies announced positive results from a study conducted by the Technion – Israel Institute of Technology, which demonstrated that its rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in supporting structured tissue formation. This suggests that Collink.3D™ could serve as a next-generation, animal-free extracellular matrix for advanced tissue engineering and research applications, potentially impacting the market for basement membrane matrices, which is projected to grow significantly by 2031.
The most recent analyst rating on (CLGN) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
Collplant Holdings’ overall stock score is primarily impacted by its poor financial performance, characterized by significant revenue and cash flow challenges. While there is some technical strength, the negative valuation metrics further weigh down the score, indicating a high-risk investment.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics. The company’s products are based on its proprietary recombinant human collagen (rhCollagen) technology, which is plant-based and aims to provide sustainable and ethical solutions in tissue repair, aesthetics, and organ manufacturing.
Average Trading Volume: 104,939
Technical Sentiment Signal: Strong Sell
Current Market Cap: $29.5M
Learn more about CLGN stock on TipRanks’ Stock Analysis page.